[CIS-PAGID] Fwd: Peripheral neuropathy in CVID

[Riedl, Marc]

I have a few, Charlotte.  Only 1 that has any issues of worsening associated with changes in Ig therapy per the discussion.  But a couple of others with polyneuropathies dx/followed by neuro.

Best,

Marc

From: <Cunningham-Rundles>, Charlotte <charlotte.cunningham-rundles at mssm.edu<mailto:charlotte.cunningham-rundles at mssm.edu>>
Reply-To: pagid listserve <pagid at list.clinimmsoc.org<mailto:pagid at list.clinimmsoc.org>>
To: pagid listserve <pagid at list.clinimmsoc.org<mailto:pagid at list.clinimmsoc.org>>
Subject: Re: [CIS-PAGID] Fwd: Peripheral neuropathy in CVID

For what it is worth, I don’t think I have seen peripheral neuropathy with CVID that I can recall.  (That would be just under 500 pts. )


On 4/19/12 9:21 AM, "Perez, Elena" <eperez2 at health.usf.edu> wrote:


>From our csl connection... Regarding neuropathy discussion from yesterday

E

Sent from my iPhone

Begin forwarded message:

From: <Elyse.Murphy at cslbehring.com>
Date: April 19, 2012 8:49:57 AM EDT
To: <eperez2 at health.usf.edu>
Subject: RE: Peripheral neuropathy in CVID

Hi Elena,
  I checked the pivotal trial safety results and there were no reports of paresthesias, numbness,  or tingling.   As you know, SCIg has been reported for use in some peripheral neuropathies ( CIDP, MMN) and CSL is  actually conducting a trial for SCIG use in CIDP  (PATH  trial ) and will be tracking among other parameters, Ig levels.   It has been well documented that there is a high comorbidity of autoimmune disorders with CVID – any idea  of incidence peripheral neuropathies in CVID?

  Dr Lederman should report this to our Pharmocovigilance dept..  I am not aware of any post marketing reports   but I will  check  with PKV and also ask Mel.

Best,
Elyse


From: Perez, Elena [mailto:eperez2 at health.usf.edu]
Sent: Wednesday, April 18, 2012 3:33 PM
To: Murphy, Elyse US/KOP
Subject: FW: Peripheral neuropathy in CVID

Fyi…(see below)
Any info on hizentra and paresthesia?


From: pagid-bounces at list.clinimmsoc.org [mailto:pagid-bounces at list.clinimmsoc.org] On Behalf Of Howard Lederman
Sent: Wednesday, April 18, 2012 3:32 PM
To:  <mailto:pagid at list.clinimmsoc.org> pagid at list.clinimmsoc.org
Subject: [CIS-PAGID] Peripheral neuropathy in CVID

I have an adult CVID patient who has developed an idiopathic peripheral neuropathy while on Hizentra.  My first reaction was to think that this was merely a coincidence and not cause and effect.  However, yesterday I received a call about an out-of-town patient who had CVID, had recently been switched from IVIG to Hizentra and then  developed parasthesias.

Do any of you have patients with similar histories?

Howard


Howard M. Lederman, M.D., Ph.D.
Professor of Pediatrics, Medicine and Pathology Division of Pediatric Allergy and Immunology Johns Hopkins Hospital - CMSC 1102 600 N. Wolfe Street Baltimore, MD 21287-3923
Phone: 410-955-5883
Fax: 410-955-0229
Email:  <mailto:Hlederm1 at jhmi.edu> Hlederm1 at jhmi.edu

WARNING: E-mail sent over the Internet is not secure.
Information sent by e-mail may not remain confidential.

DISCLAIMER: This e-mail is intended only for the individual to whom it is addressed. It may be used only in accordance with applicable laws. If you received this e-mail by mistake, please notify the sender and destroy the e-mail.

This email, including any attachments, is confidential and contains proprietary content and may be legally privileged. This transmission is intended only for the designated recipient(s), and any duplication or distribution, in any form or part, without the written consent of the sender is strictly prohibited. These confidentiality protections apply even if you received this transmission in error, in which case you should delete the message, disregard its contents and notify the sender of the mistake. CSL Behring


________________________________
IMPORTANT WARNING: This email (and any attachments) is only intended for the use of the person or entity to which it is addressed, and may contain information that is privileged and confidential. You, the recipient, are obligated to maintain it in a safe, secure and confidential manner. Unauthorized redisclosure or failure to maintain confidentiality may subject you to federal and state penalties. If you are not the intended recipient, please immediately notify us by return email, and delete this message from your computer.